Hoffmann-la Roche Inc.

Roche Glycart Ag

The Government of the United States of America As Represented by the Secretary of the Deptartment of Health and Human Services

Roche Palo Alto LLC

Guy Georges

Ekkehard Moessner

Olaf Mundigl

Ulrich Brinkmann

Stefan Dengl

Hubert Kettenberger

Joerg Moelleken

Christian Klein

Birgit Bossenmaier

Tilman Schlothauer

Jens Niewoehner

Eike Hoffmann

Stefan Seeber

Ulrich Goepfert

Wolfgang Schaefer

Michael Molhoj

Werner Scheuer

Alexander Haas

Gerhard Niederfellner

Pablo Umana

Joerg Thomas Regula

Ralf Hosse

Michael Schraeml

Sabine Imhof-Jung

Nikolaos Dimoudis

Fiona Grueninger

Klaus Kaluza

Claudia Ferrara Koller

Juergen Michael Schanzer

Valeria Lifke

Johannes Auer

Georg Fertig

Christian Scholz

Michael Gerg

Jens Fischer

Joerg Benz

Thomas Friess

Thomas Emrich

Peter Michael Huelsmann

Peter Bruenker

Wolfgang Von Der Saal

Thomas U Hofer

Hans-Willi Krell

Ulrike Reiff

Anita Kavlie

Georg Tiefenthaler

Edgar Voss

Guido Hartmann

Stefan Weigand

Sandra Grau-Richards

Matthias Rueth

Remko Griep

Monika Baehner

Inja Waldhauer

Tim Sattelkau

Rebecca Croasdale

Walter-Gunar Friebe

Pablo Umaña

Matthias Koerner

Ralf Schumacher

Petra Rueger

Carola Ries

Adelbert Grossmann

Marlene Thomas

Alexander Fidler

Hendrik Knoetgen

Martin Lanzendoerfer

Laurent Lariviere

Claudio Sustmann

Lydia Jasmin Hanisch

Kathryn Elizabeth Packman

Sonja Offner

Bernd Bohrmann

Achal Mukundrao Pashine

Samuel Moser

Maximiliane Koenig

Sebastian Dziadek

Ira H Pastan

Li Chen

Frederick Arthur Brookfield

Anja Limberg

Edward Andrew Boyd

Alfred Mertens

Stefan Scheiblich

Birgit Bramlage

Stefan Klostermann

Klaus-Peter Kuenkele

Byungkook Lee

Masanori Onda

Friederike Hesse

Klaus Mayer

Harald Duerr

Maria Amann

Xihan Wu

Sebastian Fenn

Ulrich Tibes

Matthias John

Tanja Fauti

Alexander Bujotzek

Kerstin Jahn-Hofmann

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(PS422) antibodies and methods of use

Herein is reported a method for the generation of multispecific antibodies by a half-antibody exchange reaction between two 2/3-IgGs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assemble full length bispecific antibodies. The method can be performed in the absence of reducing agents and does not require hinge region disulfide bonds in the starting 2/3-IgGs.

Method for generating multispecific antibodies from monospecific antibodies

Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.

Anti-transferrin receptor antibodies with tailored affinity

The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.

Bispecific 2+1 contorsbodies

Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

Humanized anti-human CD19 antibodies and methods of use

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Bispecific anti-CCL2 antibodies

Herein is reported a multimeric fusion polypeptide comprising five monomeric fusion polypeptides each comprising at least a Fab fragment and a COMP-domain of SEQ ID NO: 01 or a functional fragment thereof.

Compbody—a multivalent target binder

Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.

Covalently linked antigen-antibody conjugates

The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to NKG2D

The present invention relates to anti-VEGF antibodies and methods of their production and their use.

Anti-VEGF antibodies and methods of use

The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific HER2 antibodies and methods of use

Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.

Three-dimensional structure-based humanization method

The invention provides anti-BRDU antibodies and methods of using the same.

Anti-BRDU antibodies and methods of use

Growing community of inventors

Habach, Germany

Guy Georges